"Hemolysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
| Descriptor ID |
D006461
|
| MeSH Number(s) |
C23.550.403 G12.122.545
|
| Concept/Terms |
Extravascular Hemolysis- Extravascular Hemolysis
- Extravascular Hemolyses
- Hemolyses, Extravascular
- Hemolysis, Extravascular
Intravascular Hemolysis- Intravascular Hemolysis
- Hemolyses, Intravascular
- Hemolysis, Intravascular
- Intravascular Hemolyses
|
Below are MeSH descriptors whose meaning is more general than "Hemolysis".
Below are MeSH descriptors whose meaning is more specific than "Hemolysis".
This graph shows the total number of publications written about "Hemolysis" by people in this website by year, and whether "Hemolysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 2 | 3 |
| 2025 | 2 | 2 | 4 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemolysis" by people in Profiles.
-
Post-Artesunate Delayed Hemolysis in Pediatric Malaria Patients in the United States. J Pediatric Infect Dis Soc. 2024 Nov 04; 13(10):533-536.
-
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series. Pediatr Blood Cancer. 2024 Aug; 71(8):e31061.
-
Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor. Ann Clin Lab Sci. 2023 Jul; 53(4):647-652.
-
The NLRP3 inflammasome fires up heme-induced inflammation in hemolytic conditions. Transl Res. 2023 02; 252:34-44.
-
Tissue plasminogen activator in left ventricular assist device-related intravascular hemolysis after failed augmented anticoagulation. Int J Artif Organs. 2022 Nov; 45(11):911-918.
-
Hemolysis After Medication Exposure in Pediatric Patients With G6PD Deficiency. J Pediatr Hematol Oncol. 2022 07 01; 44(5):261-263.
-
"Compassionate" Cases of the Jarvik 2015 Ventricular Assist Device. ASAIO J. 2021 09 01; 67(9):1036-1043.
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
Inhibition of Hb Binding to GP1ba Abrogates Hb-Mediated Thrombus Formation on Immobilized VWF and Collagen under Physiological Shear Stress. PLoS One. 2016; 11(4):e0154276.
-
Trichinella spiralis Paramyosin Binds Human Complement C1q and Inhibits Classical Complement Activation. PLoS Negl Trop Dis. 2015 Dec; 9(12):e0004310.